Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2003-03-19
2010-06-29
Weber, Jon P (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C514S002600
Reexamination Certificate
active
07745154
ABSTRACT:
The present invention provides a preventive or therapeutic drug for a myeloma tumor and osteoclastic bone loss associating therewith, the drug containing as an active ingredient an osteopontin-production regulator or inhibitor; a screening method for a preventive or therapeutic drug for a myeloma tumor, characterized by determining osteopontin production regulatory or inhibitory effect; as well as a diagnostic kit for a myeloma tumor, characterized by including a reagent for measuring blood osteopontin level, and a diagnostic method.
REFERENCES:
patent: 2005/0119204 (2005-06-01), Chabas et al.
Bautista et al, “Quantification of Osteopontin in Human Plasma with an Elisa: Basal levels in Pre- and Postmenopausal Women”, Clinical Biochemistry, vol. 29, Jun. 1996,p. 231-239.
McPhaden et al “Plasma osteopontin levels in multiple myeloma”, Blood,1994, vol. 84, No. 10 ,suppl. 1,p. 172A.
On-line Medical Dictionary, “drug screening assays, antitumour”, www.cancerweb.ncl.ac.uk/cgi-bin/omd?drug+screening+assays,+antitumour , Dec. 12, 1998 p. 1.
Hussein et al “Multiple myeloma: present and future”, Current opinion in oncology, vol. 14(1), Jan. 2002, pp. 31-35.
Okada et al, American Journal of Physiology-Renal Physiology 2000, vol. 278:F110-F121.
Fonesca, et al., British Journal of Haematology 2000, vol. 109, p. 24-29.
Weber, Georg F. “The metastasis gene osteopontin: a candidate target for cancer therapy”, Biochimica et Biophysica Acta 1552, pp. 61-85 2001.
Kato, Yoichiro et al. “Osteopontin Expression May Be Induced by c-Src in Papillary Thyroid Carcinoma”, Acta Histochem. Cytochem, 34(3), pp. 193-199 2001.
Ue, Teruyoshi et al. “Hito Igan Saibo ni okeru osteopontin to CD44 no Kyotsu Hatsugen”, Proceedings of Japanese Research Society for Gastroenterological Carcinogenesis, vol. 9, pp. 299-300, with English translation 1997.
Tuck, Alan B. et al. “Osteopontin Expression in a Group of Lymphnode Negative Breast Cancer Patients”, Int. J. Cancer(Pred. Oncol.), vol. 79 pp. 502-508 1998.
Ue, Teruyoshi et al., “Co-Expression of Osteopontin and CD44v9 in Gastric Cancer”, Int. J. Cancer (Pred. Oncol.). vol. 79, pp. 127-132 1998.
Takahashi, Kazuhisa et al. “Hal Shikkan to Osteopontin”, Respiration Research, vol. 21, No. 7, pp. 634-639, with Partial English translation Jul. 15, 2002.
Proceedings of the American Association for Cancer Research, vol. 36, Mar. 1995 p. 222, Bautista et al.
Diosdado S. Bautista, et al.,“Inhibition of Arg-Gly-Asp (RGD)-mediated Cell Adhesion to Osteopontin by a Monoclonal Antibody against Osteopontin”, The Journal of Biological Chemistry, vol. 269, No. 37, Issue of Sep. 16, 1994, pp. 23280-23285.
Kobayashi Hideyuki
Saeki Yukihiko
Tabunoki Yuichiro
Kowa Co. Ltd.
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Schuberg Laura
Weber Jon P
LandOfFree
Preventives/remedies for myeloma tumor and method of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preventives/remedies for myeloma tumor and method of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preventives/remedies for myeloma tumor and method of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4248275